Immune Biologics

Immune Biologics Services

Cytokines. Checkpoints. Immune Modulators. Built in Microbes.

At Mika Biologics, we view the immune system as one of nature’s most powerful engines—and one of biotechnology’s greatest frontiers. The next generation of therapies, from cancer immunotherapies to regenerative medicine, will not only target cells and genes but will directly reshape immunity itself.

The foundation of this revolution is immune biologics: cytokines, checkpoint ligands, interferons, and immunomodulators that can reprogram immune responses with precision. Yet, while these molecules hold extraordinary therapeutic power, they are notoriously difficult to manufacture. Many cytokines misfold, aggregate, or lose bioactivity in conventional systems. Most large CDMOs shy away from them, leaving innovators without reliable partners.

Mika Biologics is different. We built our platform to make immune biologics not just possible, but predictable. By harnessing microbial hosts, proprietary refolding workflows, and a philosophy of elegance and efficiency, we help innovators transform cytokine concepts into clinical-grade therapies.

Mika Biologics, Microbial CDMO

What Are Immune Biologics?

Immune biologics are proteins that regulate or modulate the immune system. They include:

  • Cytokines – small proteins (e.g., IL-2, IL-7, IL-15, GM-CSF) that direct immune cell growth, survival, and differentiation.
  • Checkpoint Proteins – ligands and receptors (e.g., PD-L1, CTLA-4) that control T-cell activation or suppression.
  • Interferons – antiviral proteins that trigger innate immune defense pathways.
  • Novel Immunomodulators – engineered or synthetic proteins designed to fine-tune immune balance.

These molecules are central to modern medicine:

  • Expanding T-cells in CAR-T manufacturing.
  • Restoring immune responses in cancer immunotherapy.
  • Suppressing hyperactivation in autoimmune disease.
  • Driving regeneration in stem cell therapies.

But immune biologics are also fragile, sticky, and hard to fold. Expression in mammalian systems is slow and costly, while microbial systems often yield inactive inclusion bodies. Mika Biologics has built specialty workflows to overcome these hurdles.

Why Immune Biologics Matter

The market for immune biologics is growing exponentially, with cytokines and checkpoint modulators playing pivotal roles across therapies:

  1. Cancer Immunotherapy
    • IL-2, IL-15, and GM-CSF are being developed as adjuncts to T-cell therapies.
    • Checkpoint ligands modulate PD-1/PD-L1 pathways.
  2. Cell & Gene Therapy Expansion
    • Cytokines fuel T-cell and NK-cell growth in ex vivo expansion protocols.
    • Consistency and bioactivity are mission-critical.
  3. Autoimmunity & Inflammation
    • IL-10, interferons, and other modulators are being tested to re-balance overactive immune systems.
  4. Rare Diseases & Regeneration
    • Orphan cytokines and growth factors are increasingly linked to rare immune or metabolic disorders.

These therapies need specialized manufacturing partners who understand not just protein expression, but how to make immune proteins functional, scalable, and GMP-ready.

Our Immune Biologics Services

Mika offers a full-service portfolio for immune biologics development, built to meet clients at discovery, preclinical, or clinical stage.

1. Cytokine Expression & Development

Cytokines are central to modern immunotherapy but are challenging to express. We specialize in:

  • IL Libraries – IL-2, IL-7, IL-15, IL-21, IL-12, IL-10.
  • GM-CSF & G-CSF – colony-stimulating factors essential for immune cell proliferation.
  • Interferons – α, β, and γ interferons for antiviral and immunomodulatory use.
  • Checkpoint-Linked Cytokines – engineered cytokines fused to checkpoint domains.

Workflows:

  • Expression Optimization – microbial strains tuned for soluble yields.
  • Inclusion Body Refolding – proprietary refolding chemistries restore activity.
  • Chaperone Co-Expression – enhances folding and solubility.
  • Bioactivity Validation – receptor binding, cell-based assays, pathway activation.

At Mika, difficult cytokines are our specialty, not a problem.

2. Checkpoint Proteins & Ligands

Checkpoint pathways (PD-1/PD-L1, CTLA-4, LAG-3, TIM-3) are the master switches of immune tolerance and activation. We manufacture:

  • Ligands (PD-L1, PD-L2, Galectin-9, B7-1/B7-2)
  • Checkpoint Receptors (PD-1, CTLA-4, LAG-3)
  • Novel Fusion Proteins – checkpoint domains combined with cytokines or scaffolds.

Capabilities:

  • Expression in microbial systems with refolding workflows.
  • Glycoengineering in yeast/fungi for functional checkpoint fusion proteins.
  • High-throughput functional validation in T-cell activation assays.

By mastering checkpoint biologics in microbial hosts, we make therapies more affordable, scalable, and accessible than mammalian-only systems.

3. Interferons & Antiviral Biologics

Interferons are frontline biologics in viral defense, cancer therapy, and immune modulation. We produce:

  • IFN-α, IFN-β, IFN-γ
  • Pegylated interferons
  • Engineered interferon fusions

Services:

  • Microbial production with optimized solubility and folding.
  • Stability testing for long-term storage.
  • GMP-ready scale-up for clinical supply.

Interferons have fallen out of favor with some CDMOs due to complexity. At Mika, they are a core focus, reflecting our belief that antiviral immunity remains vital.

4. Novel Immunomodulators

The immune system is endlessly complex, and innovators are designing synthetic immune proteins to fill gaps:

  • Checkpoint-cytokine hybrids.
  • Engineered immune receptors.
  • Synthetic ligands and decoys.
  • Designer chemokines for targeted recruitment.

We support these programs with:

  • Flexible microbial expression systems.
  • Directed evolution & protein engineering.
  • Assay development for novel bioactivity.

For immune innovation, we are a strategic partner, not just a vendor.

Why Choose Mika for Immune Biologics?

Most CDMOs shy away from immune proteins due to solubility, refolding, and bioactivity challenges. Mika embraces them.

1. Microbial-First, Immune-Ready

We build E. coli, yeast, and fungal platforms designed specifically for cytokines and checkpoints.

2. Proprietary Refolding Expertise

Inclusion bodies are not dead ends. Our refolding chemistries consistently recover active cytokines and immune proteins.

3. Bioactivity at the Core

We don’t just make proteins—we validate them in functional assays (cell-based, receptor binding, signaling).

4. Orphan & Rare Capabilities

We specialize in low-volume, high-value runs for rare cytokines and modulators overlooked by larger CDMOs.

5. Global-Scale Flexibility

From R&D lots to GMP clinical batches, we adapt capacity (1 L to 2000 L in-house, 20,000 L with partners).

Technical Infrastructure

Mika Biologics operates state-of-the-art facilities for immune biologics:

  • Fermentation – stainless steel and single-use fermentors.
  • Downstream – homogenization, centrifugation, TFF, chromatography, lyophilization.
  • Refolding Suites – controlled, optimized refolding for cytokines.
  • Analytical – ELISA, qPCR, HPLC, mass spectrometry, bioassays.
  • Quality – ISO-aligned, FDA-registered, EU-compliant.

Applications & Case Examples

  • CAR-T Developer – partnered with Mika to supply IL-2 and IL-7 for T-cell expansion, achieving reproducible activity and reducing cost vs. mammalian systems.
  • Oncology Biotech – checkpoint fusion protein produced via microbial refolding, validated in T-cell assays, scaled to GMP.
  • Rare Disease Foundation – orphan cytokine supplied in small-batch GMP, enabling a Phase I trial.
  • Global Health NGO – interferon produced at scale for antiviral programs in resource-limited regions.

The Future of Immune Biologics at Mika

We see immune biologics as a pillar of next-generation medicine, and Mika is building the tools to make them real. Our future roadmap includes:

  • AI-Powered Folding Prediction – integrating machine learning to optimize solubility and refolding.
  • Glyco-Optimized Yeast Platforms – delivering human-like checkpoint fusions.
  • Immune-on-a-Chip Models – linking manufacturing to functional validation in advanced organoid models.
  • Distributed Immune Biologics – small-scale, portable systems for on-demand immune protein production.

Closing Statement

Cytokines, checkpoint proteins, interferons—these are not just molecules, but the keys to the immune future. They fuel CAR-T therapies, reprogram cancer immunity, balance autoimmunity, and unlock regenerative potential.

At Mika Biologics, we do not shy away from the hard proteins. We specialize in them. By making immune biologics scalable, soluble, and clinically functional, we enable innovators to accelerate therapies that will reshape human health.

Mika Biologics. Microbial Systems. Immune Innovation. Beyond the Cell.